Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Combined With Regorafenib in Advanced Hepatocellular Carcinoma
NCT05773105Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2023
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: 6-month Progression-Free Survival Rate at 6 weeks. Started Sep 2023; status: completed.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05773105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05773105.